Massachusetts-based VBI Vaccines Inc. announced yesterday that the U.S. FDA granted Orphan Drug Designation for VBI-1901, a bivalent vaccine candidate for the treatment of glioblastoma (GBM). VBI-1901 is a novel cancer vaccine immunotherapeutic candidate developed using...
Vax Before Cancer
/ July 7th, 2022Eliminating fake vaccine news with pharmacist, nurse, and physician review.
For more articles, try our search.